Literature DB >> 3580232

Sodium thiosulphate decreases blood cyanide concentrations after the infusion of sodium nitroprusside.

P V Cole, C J Vesey.   

Abstract

Plasma and red cell cyanide, and plasma thiocyanate, concentrations were measured in 30 patients undergoing elective nitroprusside-induced hypotension. One randomly selected group (n = 15), who received 0.21-0.70 mg kg-1 over periods of 50-160 min, were given a bolus of sodium thiosulphate 10.6-38.5 mg kg-1 immediately on cessation of the nitroprusside administration. The other group, who received infusions of 0.11-0.85 mg kg-1 for periods of 59-197 min, received no antidote. Cyanide concentrations, expressed as a percentage of the immediate post-infusion values, were significantly lower in the treated group in all subsequent blood samples (at 10, 30 and 60 min; plasma cyanide P less than 0.05; red cell cyanide P less than 0.001). Improved cyanide metabolism was further demonstrated by a sharp increase in mean plasma thiocyanate concentration (P less than 0.05) in the group receiving the antidote.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3580232     DOI: 10.1093/bja/59.5.531

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  3 in total

Review 1.  Drug treatment of hypertensive crisis in children.

Authors:  Christopher A Thomas
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

2.  Sodium nitroprusside is not associated with metabolic acidosis during intraoperative infusion in children.

Authors:  Gregory B Hammer; Sara G Connolly; Scott R Schulman; Andrew Lewandowski; Carol Cohane; Tammy L Reece; Ravinder Anand; Jeff Mitchell; David R Drover
Journal:  BMC Anesthesiol       Date:  2013-04-30       Impact factor: 2.217

3.  Evaluation of sodium nitroprusside for controlled hypotension in children during surgery.

Authors:  David R Drover; Gregory B Hammer; Jeffrey S Barrett; Carol A Cohane; Tammy Reece; Anne Zajicek; Scott R Schulman
Journal:  Front Pharmacol       Date:  2015-07-06       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.